Close Menu

NEW YORK – Oncocyte said on Thursday that it has entered a distribution agreement with ProGenetics, expanding the commercial availability of its DetermaRx test to Israel. Financial and other terms were not disclosed.

DetermaRx is a treatment stratification test that identifies patients at high risk for lung cancer recurrence who may benefit from adjuvant chemotherapy after tumor removal surgery. Oncocyte launched the test in the United States through an early-access program in late January, which it said has now expanded to over 40 sites.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.